Coromandel International Q4 FY25: Profit jumps 3.6x

Coromandel International’s Q4 FY25 results triggered a strong market reaction, with the stock rising about 5% to ₹2,325 after multiple reports flagged a sharp year-on-year surge in quarterly profit. Alongside earnings, the company also highlighted crop protection and bio products momentum and a dividend announcement, keeping investor attention on both core fertiliser operations and higher-margin agri-solutions.

The quarter’s numbers, however, were reported across different disclosures and summaries, with some variance in headline revenue and profit figures. What remains consistent across the company commentary and business review is the role of volume-led growth, an improved crop protection mix, and better profitability in key molecules across domestic and export markets.

Stock reaction and headline triggers

Shares of Coromandel International were reported to have risen 5% to ₹2,325 on Thursday after the company’s Q4 FY25 performance beat expectations in some market commentary. Media reports also described net profit rising more than 3.6x year-on-year to around ₹579.7 crore for the March 2025 quarter.

The spike in reported profit came alongside an improvement in operating performance, with EBITDA for the quarter cited at about ₹426.4 crore in one report, and ₹426 crore in management commentary. Operating margin was also reported to have improved to 8.55% from 7% in the comparable quarter, supported by price management and cost discipline.

Consolidated income: company commentary vs other summaries

In the earnings call-style commentary included in the provided text, the company said consolidated total income was ₹5,114 crore in Q4, compared with ₹3,996 crore in the corresponding period last year. It also stated full-year consolidated total income of ₹24,444 crore versus ₹22,290 crore a year ago, implying 28% growth for the quarter and 10% for the full year.

Separately, other snippets in the same input mention quarterly revenues of ₹4,988.4 crore versus ₹3,912.7 crore in Q4 FY24. And a “Financial Statements for Q4FY25” table lists total income of ₹3,996.25 crore for the quarter-ended March, with Q3 FY25 total income at ₹7,048.86 crore and Q4 FY24 total income at ₹5,522.68 crore. Because these figures appear together in the source text, investors tracking the company typically reconcile differences by checking the exact definition being used (for example, total income vs revenue from operations) and the underlying period labels.

EBITDA: quarter and full-year trends

Management commentary in the source text put consolidated EBITDA at ₹426 crore for Q4, up from ₹273 crore in the year-ago quarter. For the full year, consolidated EBITDA was stated at ₹2,628 crore versus ₹2,399 crore in the previous year, with the improvement attributed to volume growth across businesses and margin expansion in the crop protection segment.

A separate results note in the text also reported Q4 EBITDA of ₹438 crore versus ₹269 crore in the comparable quarter, and FY24-25 EBITDA of ₹2,656 crore versus ₹2,401 crore. While the exact values vary across items included in the input, the direction of change described is the same: higher operating profit year-on-year.

Profit numbers: large YoY jump reported

Multiple reports in the input cite a steep year-on-year rise in Q4 net profit. One item stated consolidated net profit of ₹579.7 crore, while another cited ₹578.45 crore compared with ₹163.92 crore in Q4 FY24. A separate business update note also mentioned PAT of ₹578 crore versus ₹164 crore.

In the longer “CIL FY 24-25 Q4 & Full Year Results” section embedded in the text, consolidated PAT for the quarter was listed as ₹578 crore versus ₹164 crore. For the year, that same section listed PAT at ₹2,055 crore versus ₹1,641 crore.

Crop protection and bio: growth led by formulations

The crop protection and bio business was a key focus area in the commentary. The text states that revenue from the crop protection business rose 7% to ₹2,637 crore, led by higher sales in formulations, which grew 16%. Exports grew 5%, and the bio business grew 9%.

Profitability also improved, with EBIT stated to be up by 25% to ₹363 crore, aided by improved demand for key molecules in both domestic and export markets. The performance of new products and captive molecules was also cited as supporting profitability.

In the business review section provided, crop protection revenue for FY24-25 was also listed at ₹2,635 crore versus ₹2,454 crore in the previous year, with profit before interest and tax at ₹366 crore versus ₹288 crore.

Fertiliser and nutrient business: scale remains the anchor

The “Nutrient and Allied Business” segment remained the company’s largest contributor in the business review included in the input. For Q4, segment revenue was stated at ₹4,326 crore versus ₹3,358 crore a year ago. Profit before interest and tax for the segment was listed at ₹312 crore versus ₹248 crore.

For FY24-25, nutrient and allied revenue was reported at ₹21,633 crore versus ₹19,749 crore, with profit before interest and tax at ₹2,244 crore versus ₹2,176 crore.

Subsidy vs non-subsidy mix: what management disclosed

The company commentary included a breakdown of subsidy and non-subsidy share. For the last quarter, the subsidy and non-subsidy share of business was stated at 79% and 21%, versus 78% and 22% a year ago. For the full year, it was stated as 82% and 18%, compared with 83% and 17% in the prior year.

For profitability mix, the commentary stated the subsidy and non-subsidy share stood at 67% and 33% during the quarter, versus 53% and 47% in the previous year. For the full year, it was stated at 70% and 30%, compared with 72% and 28% previously.

Dividend and capital allocation updates

The Board was stated to have approved a dividend of ₹9 per share. Another report in the input described a total dividend of ₹9 per equity share for FY25 comprising a final dividend of ₹6 and a special dividend of ₹3 per share, with a record date of July 17, 2025 and dispatch on or before August 23, 2025.

The same report also said the Board approved an equity investment of up to ₹65 crore in wholly owned subsidiary Coromandel Chemicals Ltd, with funds to be used to drive joint venture business prospects in gypsum-based building materials and support a new vertical.

Key numbers snapshot (as stated in the input)

Why the quarter mattered for investors

Beyond the headline profit jump, the input text points to two operational themes investors often track for Coromandel. First, crop protection profitability improved with better demand for key molecules and traction in formulations, exports, and bio products. Second, the company continued to emphasise volume growth across businesses, which was cited as a key driver of year-on-year expansion in consolidated EBITDA.

The dividend announcement and the proposed ₹65 crore investment into Coromandel Chemicals also signalled active capital allocation during a period when management is positioning the company beyond mainstream fertiliser and agri-inputs.

Conclusion

Coromandel International’s Q4 FY25 updates combined strong year-on-year profit growth with improved crop protection profitability and a ₹9 per share dividend declaration, supporting positive market reaction. The next set of updates investors will track are the execution milestones around the subsidiary investment and the dividend record date and dispatch timelines stated in the reports.